Fortress Biotech shares surge 13.39% premarket after subsidiary Cyprium sells Rare Pediatric Disease Priority Review Voucher for $205 million.

Fortress Biotech surged 13.39% in premarket trading following its subsidiary Cyprium Therapeutics’ announcement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million. The PRV, earned after the FDA approved ZYCUBO for Menkes disease in January 2026, was transferred to Cyprium under its agreement with Sentynl Therapeutics. The transaction, pending regulatory clearance, provides immediate liquidity and aligns with Cyprium’s strategy to monetize value-generating assets. Management highlighted the PRV sale as part of a broader success, including three FDA approvals and a recent subsidiary sale, reinforcing investor confidence in the company’s portfolio execution. The proceeds will also fund future development, with Cyprium retaining royalties and milestones from ZYCUBO. This strategic move underscores Fortress Biotech’s focus on leveraging regulatory milestones to strengthen its financial position and pipeline advancement.